Lymphocytes, Activated

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

CompletedNCT00000756

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2002-06-30Target: 15Updated: 2021-11-03

Unknown Phase

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

TerminatedNCT00000875

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2003-04-30Target: 16Updated: 2016-12-14

A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

TerminatedNCT00000824

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2005-06-30Updated: 2016-12-14